Development of a Blood-Based Biomarker Panel for Indeterminate Lung Nodules

Abstract

Lung cancer screening with low-dose CT (LDCT) has been shown to reduce mortality by 20 , although there are concerns including high false positivity, cost, and radiation exposure. Blood-based markers are a promising and attractive approach to complement LDCT because of the potential to identify those subjects that need to undergo further work-up for their indeterminate nodules. The main objective of my proposed project is to develop a blood-based biomarker panel from three platforms (protein, autoantibody and microRNA) to distinguish malignant lung nodules from benign lung nodules. We have so far assayed 20 protein markers, 122 autoantibodies, 20 microRNAs, and a metabolite DAS, in the 149 malignant lung nodules and 187 benign lung nodules.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Sep 01, 2016
Accession Number
AD1046770

Entities

People

  • Ayumu Taguchi

Organizations

  • University of Texas at Austin

Tags

DTIC Thesaurus Topics

  • Biological Markers
  • Biomedical Research
  • Cancer
  • Cancer Screening
  • Computational Biology
  • Education
  • Lung Cancer
  • Metabolites
  • Neoplasms
  • Platforms
  • Professional Development
  • Radiation
  • Risk Factors
  • Students
  • Systems Biology
  • Technology Transfer
  • Training

Fields of Study

  • Medicine

Readers

  • Oncology and Biomarker-Based Cancer Detection.